The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study

Not Applicable

Recruiting

• Conditions: Healthy
• Interventions: Drug: Placebo; Drug: Vasopressin

• Registration Number: NCT06329037
• Lead Sponsor: University of Electronic Science and Technology of China

Brief Summary

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Detailed Description

Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. Initial studies have employed intranasal AVP during a socio-emotional eye tracking paradigm and reported effects on both, top-down as well as bottom-up control. Within this context the present study aims to validate the effects of orally administered AVP on top-down and bottom-up attentional control towards socio-affective stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a saccade/anti-saccade task 45 minutes after administration. The task paradigm will encompass social (happy, angry, fearful, sad and neutral faces) and non-social (oval) stimuli to examine the social and emotion-specific effects of oral vasopressin.

Study Timeline

• Study Start: 2024-03-05
• Study First Submitted: 2024-03-15
• Study First Submitted QC: 2024-03-15
• Study First Posted: 2024-03-25
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-09
• Last Update Posted: 2024-04-11
• Primary Completion: 2025-06-01
• Study Completion: 2025-07-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.

Normal or corrected-normal version

Exclusion Criteria

• History of neuropsychiatric diseases.
• History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
• History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
• History of renal diseases, including renal stones or renal failure.
• History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
• Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
• Infections such as COVID-19 or influenza, or unexplained fever.
• Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
• History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
• Blood donation (≤ 1 month prior to administration).
• Take oral contraceptives or receive hormonal medications in the three months prior to the experiment.
• Pregnant or breastfeeding.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo group	Placebo	Placebo
Vasopressin group	Vasopressin	Vasopressin (20IU)

Primary Outcome Measures

Name	Time	Method
Saccade/antisaccade latency difference between social and non-social stimuli after oral vasopressin administration	45 minutes - 75 minutes after treatment	Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions.
Error rate of saccade/antisaccade for social versus non-social stimuli after oral vasopressin administration	45 minutes - 75 minutes after treatment	Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions.

Secondary Outcome Measures

Name	Time	Method
Error rate of saccade/antisaccade for different facial emotions after oral vasopressin administration	45 minutes - 75 minutes after treatment	Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin and placebo treatment conditions.
Saccade/antisaccade latency for different facial emotions after oral vasopressin administration	45 minutes - 75 minutes after treatment	Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions.

Trial Locations

Locations (1)

University of Electronic Science and Technology of China; 🇨🇳 Chengdu, Sichuan, China